曲妥珠单抗治疗HER2阳性晚期胃癌血液/骨髓药物不良反应的Meta分析

Drug Adverse Reaction on Blood / Bone Marrow Treat HER-2 Positive Advanced Gastric Cancer with Trastuzumab: A Meta-analysis

目的通过文献数据Meta分析探讨曲妥珠单抗联合用药治疗HER2阳性胃癌血液/骨髓的药物不良反应。方法以研究目标为标准检索曲妥珠单抗治疗HER2阳性晚期胃癌的临床研究,收集研究中的观察人数和血液/骨髓药物不良反应人数,计算其不良反应统计学参数并用Rev Man5.3进行二分类数据率的Meta分析。结果血液/骨髓不良反应的合并整体效应OR=1.61,95%CI=1.43~1.82,P〈0.01,具有统计学意义。结论曲妥珠单抗联合其他化疗药物治疗HER2阳性晚期胃癌,发生血液/骨髓药物不良反应的比例即比数比（OR）是不发生者的1.61倍。

OBJECTIVE To analyse adverse drug reactions of trastuzumab combination therapy in the treatment of HER2 positive stomach cancer blood / bone marrow through literature data meta-analysis. METHODS Aimed for standard retrieval of clinical research of trastuzumab treating HER2 positive advanced gastric cancer,collect observation number in the research and blood / bone marrow adverse drug reaction number,calculate the statistical parameters of the adverse reactions and binary data rate of the meta analysis was performed with Rev Man5. 3. RESULTS OR= 1. 61,P〈0. 01,and 95% CI = 1. 43 ~ 1. 82 were statistically significant in the combined effect of blood and bone marrow. CONCLUSION When Trastuzumab in combination with other chemotherapy drugs is used in the treatment of HER2 positive advanced gastric cancer,the ratio of blood / bone marrow of adverse drug reactions is 1. 61 times higher than that of those adverse drug reactions which are not occurring.